295% Pop: Too Late to Buy Puma Biotechnology Stock?

Puma Biotechnology (PBYI) reported surprising phase 3 data that sent shares soaring. Here's what you need to know about Puma's promising cancer drug.

Jul 23, 2014 at 5:15PM

Puma Biotechnology (NYSE:PBYI) surged more than 200% after the bell on Tuesday after reporting that its development-stage cancer drug neratinib scored an important victory in phase 3 trials.

The news surprised investors, whose worries over side effects in previous trials caused shares to fall by more than 50%, as shares held short increased from 1.5 million to nearly 1.7 million, or roughly 8% of all Puma's shares available for trading.

Delivering the goods
Investing in biotechnology stocks is notoriously hit-and-miss, and Puma's roller-coaster ride over the past year serves as an important reminder that risk-averse investors should stay at bay when it comes to the rollicking industry.

But that's not the only lesson to be learned from Puma's pop-and-drop history.

The company's dramatic rise on Tuesday afternoon also reminds investors that short-term news shouldn't dictate long-term investment decisions

That's because what may seem bad today may not be viewed as bad tomorrow, particularly when it comes to hard-to-treat disease like cancer.

It was only a month ago that the revelation of moderate to severe diarrhea in neratinib patients had investors overlooking what appeared to be otherwise solid trial results.


Source: Puma Biotechnology

Updating results
In phase 3, neratinib has again posted impressive results.

Patients with HER2-positive breast cancer who were treated with neratinib in a 2,800-person trial did better than those who received a placebo following treatment with Herceptin.

Neratinib patients saw a 33% improvement in disease-free survival over the control group, and that has Puma aiming for an FDA filing of neratinib in the extended adjunctive setting in the first half of 2015.

Why that matters
The U.S. spent $16.5 billion on breast cancer treatment in 2010, and as much as $25 billion could be spent treating the disease by 2020, according to the National Cancer Institute.


Source: National Cancer Institute

One of the reasons for the jump in spending is an ever-climbing number of patients diagnosed with the disease. According to the World Health Organization, 1.4 million new cases of breast cancer are diagnosed each year. As a result, the National Cancer Institute estimates that the number of Americans diagnosed with breast cancer will climb from 3.46 million in 2010 to 4.33 million people in 2020.

Fool-worthy final thoughts
The man behind Puma is CEO Alan Auerbach, the same person who successfully developed Johnson & Johnson's blockbuster Zytiga, which J&J acquired when it bought Auerbach's Cougar Biotechnology for $1 billion in 2009.

Auerbach acquired neratinib from Pfizer in 2011, and it's anyone's guess whether he hopes to sell Puma, too. If so, those potential acquirers will have to pay a lot more than they would've had to pay a month ago, and that's a lesson investors may want to remember.

Leaked: This coming blockbuster may make even Puma jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. To that end, there is a product in development that will change how we treat a common chronic illness and also potentially revolutionize the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers